HC Wainwright Reaffirms “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

HC Wainwright reiterated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $35.00 target price on the stock.

A number of other analysts have also recently issued reports on STOK. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Chardan Capital began coverage on Stoke Therapeutics in a report on Friday, December 20th. They set a “buy” rating and a $24.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Stock Down 3.8 %

STOK opened at $8.96 on Wednesday. Stoke Therapeutics has a 12-month low of $4.09 and a 12-month high of $17.58. The stock has a market cap of $474.58 million, a price-to-earnings ratio of -4.27 and a beta of 0.95. The business has a 50 day moving average of $12.05 and a 200-day moving average of $13.11.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. As a group, analysts expect that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insider Activity

In related news, General Counsel Jonathan Allan sold 9,696 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $123,914.88. Following the transaction, the general counsel now directly owns 35,142 shares of the company’s stock, valued at approximately $449,114.76. This represents a 21.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 6,170 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the sale, the chief executive officer now directly owns 68,671 shares of the company’s stock, valued at $877,615.38. This represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock valued at $809,421 in the last ninety days. 11.30% of the stock is owned by company insiders.

Institutional Trading of Stoke Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC bought a new stake in Stoke Therapeutics during the 2nd quarter worth approximately $29,000. Intech Investment Management LLC bought a new position in shares of Stoke Therapeutics in the third quarter valued at approximately $160,000. The Manufacturers Life Insurance Company grew its holdings in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares in the last quarter. Mesirow Financial Investment Management Inc. bought a new position in shares of Stoke Therapeutics in the third quarter valued at approximately $192,000. Finally, Profund Advisors LLC bought a new position in shares of Stoke Therapeutics in the second quarter valued at approximately $201,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.